Table 1. Patient demographics and clinical and electrophysiological profiles.
| Variable | Healthy controls | Type 2 diabetes | ||
|---|---|---|---|---|
| G0 | G1 | G2+3 | ||
| TNSr (score) | - | 0(0.00) | 4.06(2.28) | 11.46(2.05) |
| Sex: male/female (number) | 14/19 | 9/18 | 26/25 | 18/10 |
| Age (yr.) | 62.11(7.51) | 61.19(8.15) | 62.37(12.90) | 63.00(10.85) |
| HbA1c (mg/dl) | 5.90(0.51) | 7.12(0.76)*** | 7.77(1.42)*** | 7.82(1.76)*** |
| Creatinine (mg/dl) | 0.75(0.16) | 0.78(0.24) | 0.87(0.32)* | 1.26(1.73) |
| Body weight (kg) | 61.07 (10.21) | 65.89 (10.80) | 67.34 (12.68) | 68.81 (12.09) |
| Diabetes duration (yr. since diagnosis) |
N/A | 3.27 (3.39) | 5.79 (4.31) | 6.48 (4.48) |
| Diabetes medications | N/A | Insulin (8%), Biguanides (58%), SU (16%), Acarbose (13%), Meglitinides (3%), DPP-4i (34%), Thiazolidinediones (0%) | Insulin (22%), Biguanides (76%), SU (27%) Acarbose (5%), Meglitinides (2%), DPP-4i (27%), Thiazolidinediones (0%) | Insulin (19%), Biguanides (67%), SU (48%), Acarbose (10%), Meglitinides (0%), DPP-4i (29%), Thiazolidinediones (5%) |
The reported values of laboratory data represent the mean (standard deviation).
TNSr = Total neuropathy score-reduced [14], SU = sulfonylureas, and DPP-4i = dipeptidyl peptidase 4 inhibitors.
*t-test P<0.05 vs. healthy controls and
***t-test P<0.001 vs. healthy controls.